Therapeutic considerations for Mdm2: Not just a one trick pony

Jason A. Lehman, Jacob A. Eitel, Christopher N. Batuello, Lindsey D. Mayo

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Background: The mdm2 proto-oncogene is elevated in numerous late stage cancers. The Mdm2 protein manifests its oncogenic properties in part through inactivation of the tumor suppressor protein p53. Recent efforts in anticancer drug design have focused on the identification of small molecules that disrupt the Mdm2-p53 interaction, in hope of re-engaging the p53 pathway. Objective: In addition to binding p53, Mdm2 complexes with numerous proteins involved in DNA repair, translation, metabolic activities, tumor growth and apoptosis. Further biochemical analysis is required to understand how Mdm2 integrates into all of these cellular processes. Post-translational modifications to Mdm2 can alter its ability to associate with numerous proteins. Changes in protein structure may also affect the ability of small molecule inhibitors to effectively antagonize Mdm2. Conclusion: The complexity of Mdm2 modification has been largely neglected during the development of previous Mdm2 inhibitors. Future high-throughput or in silico screening efforts will need to recognize the importance of post-translational modifications to Mdm2. Furthermore, the identification of molecules that target other domains in Mdm2 may provide a tool to prevent other pivotal p53-independent functions of Mdm2. These aims provide a useful roadmap for the discovery of new Mdm2-binding compounds with therapeutic potency that may exceed its predecessors.

Original languageEnglish (US)
Pages (from-to)1309-1321
Number of pages13
JournalExpert Opinion on Drug Discovery
Volume3
Issue number11
DOIs
StatePublished - Nov 1 2008

Fingerprint

Post Translational Protein Processing
Proto-Oncogene Proteins c-mdm2
Tumor Suppressor Protein p53
Proteins
Proto-Oncogenes
Drug Design
DNA Repair
Computer Simulation
Neoplasms
Therapeutics
Apoptosis
Growth

Keywords

  • DNA-dependent protein kinase
  • Hdm2
  • Mdm2
  • Mdmx
  • Nutlin compounds
  • P53
  • RING domain
  • Small molecule inhibitors

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Therapeutic considerations for Mdm2 : Not just a one trick pony. / Lehman, Jason A.; Eitel, Jacob A.; Batuello, Christopher N.; Mayo, Lindsey D.

In: Expert Opinion on Drug Discovery, Vol. 3, No. 11, 01.11.2008, p. 1309-1321.

Research output: Contribution to journalReview article

Lehman, Jason A. ; Eitel, Jacob A. ; Batuello, Christopher N. ; Mayo, Lindsey D. / Therapeutic considerations for Mdm2 : Not just a one trick pony. In: Expert Opinion on Drug Discovery. 2008 ; Vol. 3, No. 11. pp. 1309-1321.
@article{81ed6a606b8646148cee274d639b789a,
title = "Therapeutic considerations for Mdm2: Not just a one trick pony",
abstract = "Background: The mdm2 proto-oncogene is elevated in numerous late stage cancers. The Mdm2 protein manifests its oncogenic properties in part through inactivation of the tumor suppressor protein p53. Recent efforts in anticancer drug design have focused on the identification of small molecules that disrupt the Mdm2-p53 interaction, in hope of re-engaging the p53 pathway. Objective: In addition to binding p53, Mdm2 complexes with numerous proteins involved in DNA repair, translation, metabolic activities, tumor growth and apoptosis. Further biochemical analysis is required to understand how Mdm2 integrates into all of these cellular processes. Post-translational modifications to Mdm2 can alter its ability to associate with numerous proteins. Changes in protein structure may also affect the ability of small molecule inhibitors to effectively antagonize Mdm2. Conclusion: The complexity of Mdm2 modification has been largely neglected during the development of previous Mdm2 inhibitors. Future high-throughput or in silico screening efforts will need to recognize the importance of post-translational modifications to Mdm2. Furthermore, the identification of molecules that target other domains in Mdm2 may provide a tool to prevent other pivotal p53-independent functions of Mdm2. These aims provide a useful roadmap for the discovery of new Mdm2-binding compounds with therapeutic potency that may exceed its predecessors.",
keywords = "DNA-dependent protein kinase, Hdm2, Mdm2, Mdmx, Nutlin compounds, P53, RING domain, Small molecule inhibitors",
author = "Lehman, {Jason A.} and Eitel, {Jacob A.} and Batuello, {Christopher N.} and Mayo, {Lindsey D.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1517/17460441.3.11.1309",
language = "English (US)",
volume = "3",
pages = "1309--1321",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Therapeutic considerations for Mdm2

T2 - Not just a one trick pony

AU - Lehman, Jason A.

AU - Eitel, Jacob A.

AU - Batuello, Christopher N.

AU - Mayo, Lindsey D.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Background: The mdm2 proto-oncogene is elevated in numerous late stage cancers. The Mdm2 protein manifests its oncogenic properties in part through inactivation of the tumor suppressor protein p53. Recent efforts in anticancer drug design have focused on the identification of small molecules that disrupt the Mdm2-p53 interaction, in hope of re-engaging the p53 pathway. Objective: In addition to binding p53, Mdm2 complexes with numerous proteins involved in DNA repair, translation, metabolic activities, tumor growth and apoptosis. Further biochemical analysis is required to understand how Mdm2 integrates into all of these cellular processes. Post-translational modifications to Mdm2 can alter its ability to associate with numerous proteins. Changes in protein structure may also affect the ability of small molecule inhibitors to effectively antagonize Mdm2. Conclusion: The complexity of Mdm2 modification has been largely neglected during the development of previous Mdm2 inhibitors. Future high-throughput or in silico screening efforts will need to recognize the importance of post-translational modifications to Mdm2. Furthermore, the identification of molecules that target other domains in Mdm2 may provide a tool to prevent other pivotal p53-independent functions of Mdm2. These aims provide a useful roadmap for the discovery of new Mdm2-binding compounds with therapeutic potency that may exceed its predecessors.

AB - Background: The mdm2 proto-oncogene is elevated in numerous late stage cancers. The Mdm2 protein manifests its oncogenic properties in part through inactivation of the tumor suppressor protein p53. Recent efforts in anticancer drug design have focused on the identification of small molecules that disrupt the Mdm2-p53 interaction, in hope of re-engaging the p53 pathway. Objective: In addition to binding p53, Mdm2 complexes with numerous proteins involved in DNA repair, translation, metabolic activities, tumor growth and apoptosis. Further biochemical analysis is required to understand how Mdm2 integrates into all of these cellular processes. Post-translational modifications to Mdm2 can alter its ability to associate with numerous proteins. Changes in protein structure may also affect the ability of small molecule inhibitors to effectively antagonize Mdm2. Conclusion: The complexity of Mdm2 modification has been largely neglected during the development of previous Mdm2 inhibitors. Future high-throughput or in silico screening efforts will need to recognize the importance of post-translational modifications to Mdm2. Furthermore, the identification of molecules that target other domains in Mdm2 may provide a tool to prevent other pivotal p53-independent functions of Mdm2. These aims provide a useful roadmap for the discovery of new Mdm2-binding compounds with therapeutic potency that may exceed its predecessors.

KW - DNA-dependent protein kinase

KW - Hdm2

KW - Mdm2

KW - Mdmx

KW - Nutlin compounds

KW - P53

KW - RING domain

KW - Small molecule inhibitors

UR - http://www.scopus.com/inward/record.url?scp=56749163496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749163496&partnerID=8YFLogxK

U2 - 10.1517/17460441.3.11.1309

DO - 10.1517/17460441.3.11.1309

M3 - Review article

AN - SCOPUS:56749163496

VL - 3

SP - 1309

EP - 1321

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 11

ER -